GSK global strengthens commitment to Lanka

GlaxoSmithKline (GSK) has made a foreign direct investment of $ 11 m to expand its operations in Sri Lanka.

Managing Director of GSK Consumer Healthcare, T. S. Dayanand said, "Over the years, we have consistently invested in Sri Lanka. This new investment will enable us to bring more new products to our consumers. It will also help us localise more of our products and reduce dependence on imports."

A spokesman for GSK said, "Promoting local manufacture earlier this year, GSK Sri Lanka inaugurated a new state-of-the-art tablet manufacturing facility in Ratmalana. The new facility was the result of a Rs. 217 m investment. It will strengthen local operations and raise the pharmaceutical manufacturing capability while saving foreign exchange."

"GlaxoSmithKline conducts research into new medicines and innovative healthcare products and supports the development goals of the country through meaningful investment," he said.Currently employing over 500 people directly and indirectly, GSK also works with 70 distributors.